Group One Trading
XFOR icon

Group One Trading’s X4 Pharmaceuticals XFOR Stock Holding History

Group One Trading’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,300
Closed -$72.8K – 9307
2025
Q3 		$72.8K Hold
21,300
– – ﹤0.01% 5633
2025
Q2 		$40.5K Buy
21,300
+20,590
+2,900% +$84.3K ﹤0.01% 5746
2025
Q1 		$5.04K Sell
710
-2,617
-79% -$36K ﹤0.01% 6643
2024
Q4 		$73.2K Sell
3,327
-120
-3% -$1.91K ﹤0.01% 4777
2024
Q3 		$69.2K Sell
3,447
-96
-3% -$2K ﹤0.01% 4435
2024
Q2 		$61.7K Sell
3,543
-740
-17% -$24.2K ﹤0.01% 4365
2024
Q1 		$179K Sell
4,283
-7,314
-63% -$203K ﹤0.01% 3655
2023
Q4 		$292K Buy
11,597
+2,547
+28% +$61.9K ﹤0.01% 3528
2023
Q3 		$296K Sell
9,050
-5,640
-38% -$246K ﹤0.01% 3448
2023
Q2 		$855K Buy
14,690
+14,353
+4,259% +$738K ﹤0.01% 2497
2023
Q1 		$8.79K Buy
337
+334
+11,133% +$9.79K ﹤0.01% 6004
2022
Q4 		$99 Buy
+3
New +$142 ﹤0.01% 7074
2022
Q2 		– Sell
-5,130
Closed -$269K – 8631
2022
Q1 		$269K Buy
5,130
+5,117
+39,362% +$293K ﹤0.01% 4484
2021
Q4 		$1K Buy
+13
New +$1.64K ﹤0.01% 8041

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Group One Trading's XFOR Position: Q1 2026 in Review

Group One Trading reduced its X4 Pharmaceuticals (XFOR) stake by 82% in Q1 2026, selling an estimated $12.3K and leaving 712 shares worth $2.94K. The position accounts for ﹤0.01% of the portfolio, ranked #6931.

Group One Trading first reported a position in XFOR in Q3 2021 and has held it in 18 quarters since. The position peaked at $632K in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Group One Trading held 712 shares of X4 Pharmaceuticals worth $2.94K as of Q1 2026.
  • Group One Trading sold 3,286 X4 Pharmaceuticals shares in Q1 2026, an estimated $12.3K.
  • X4 Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6931 holding.
  • Group One Trading first reported a position in X4 Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Group One Trading's X4 Pharmaceuticals position peaked at $632K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.